Ali Daftarian, MD
Pain Medicine · Bryan, TXNPI 1407018021
Payments from drug & device makers
Across 108 payments — averaging $62.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$2K
- Stryker$1K
- Genesys Orthopedics Systems, L.L.C.$921
- Boston Scientific$282
- Nalu Medical, Inc.$142
- plus $376 from 5 others
What the payments were for
- Travel & lodging$3,14647%
- Food & beverage$3,53152%
- Education$591%
- Gifts$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 33 | $1,927 |
| Abbott | 42 | $1,841 |
| Stryker | 5 | $1,263 |
| Genesys Orthopedics Systems, L.L.C. | 6 | $921 |
| Boston Scientific | 10 | $282 |
| Nalu Medical, Inc. | 1 | $142 |
| Vertos Medical, Inc. | 2 | $141 |
| Pacira Pharmaceuticals Incorporated | 1 | $125 |
| MDD US Operations, LLC | 4 | $60 |
| Pfizer | 2 | $27 |
| Biodelivery Sciences International, Inc. | 2 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SACROILIAC JOINT FUSION SYSTEM$1,790
- OPTABLATE$1,141
- SPINEJACK$1,141
- INTELLIS$1,000
- Cardiovascular- Research only$535
- ETERNA$245
- OCTRODE$170
- VANTA ADAPTIVESTIM$158
- Nalu Neurostimulation System$142
- IOVERA SYSTEM$125
- mild Device Kit$121
How this compares
$6,751 in reported general payments places this provider in the 65th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 55 | $53,452 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,264 | $30,334 |
| Fentanyl | 127 | $11,885 |
| MovantikNaloxegol Oxalate | 17 | $9,821 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 215 | $7,128 |
| Gabapentin | 338 | $5,077 |
| Morphine Sulfate ErMorphine Sulfate | 137 | $3,943 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 142 | $3,543 |
| Tramadol Hcl ErTramadol Hcl | 37 | $3,250 |
| Pregabalin | 130 | $2,183 |
| Tramadol Hcl | 160 | $2,013 |
| Tizanidine Hcl | 193 | $1,783 |
| Celecoxib | 52 | $1,209 |
| Duloxetine Hcl | 56 | $1,030 |
| Methocarbamol | 36 | $724 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Bryan
- Aaron CalodneyTyler$3M
- Mitchell EngleHouston$1.5M
- Melissa MurphyGrapevine$711K
- Shiraz YazdaniLubbock$632K
- Muhammad ZulqarnainDallas$556K
- Daniel PakHouston$460K
- Marvin ChangSugar Land$306K
- David LeimanHouston$281K
- Candice BurnetteSugar Land$265K
- Ellen LinSan Antonio$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.